[Inn-Spanish] en es it fr

[Inn-Spanish] Brand names, [Inn-Spanish] Analogs

[Inn-Spanish] Brand Names Mixture

  • No information avaliable

[Inn-Spanish] Chemical_Formula

C4H7N1O4

[Inn-Spanish] RX_link

No information avaliable

[Inn-Spanish] fda sheet

[Inn-Spanish] msds (material safety sheet)

http://domino.solutia.com/solutia/smsdslib.nsf/0/561ad1a8b4bae67c8625636000511152/$FILE/English.pdf

[Inn-Spanish] Synthesis Reference

No information avaliable

[Inn-Spanish] Molecular Weight

133.104 g/mol

[Inn-Spanish] Melting Point

230 oC

[Inn-Spanish] H2O Solubility

4.5 g/l

[Inn-Spanish] State

Solid

[Inn-Spanish] LogP

-0.67 +/- 0.36

[Inn-Spanish] Dosage Forms

Capsules and powder

[Inn-Spanish] Indication

There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids.

[Inn-Spanish] Pharmacology

L-aspartate is considered a non-essential amino acid, meaning that, under normal physiological conditions, sufficient amounts of the amino acid are synthesized in the body to meet the body's requirements. L-aspartate is formed by the transamination of the Krebs cycle intermediate oxaloacetate. The amino acid serves as a precursor for synthesis of proteins, oligopeptides, purines, pyrimidines, nucleic acids and L-arginine. L-aspartate is a glycogenic amino acid, and it can also promote energy production via its metabolism in the Krebs cycle. These latter activities were the rationale for the claim that supplemental aspartate has an anti-fatigue effect on skeletal muscle, a claim that was never confirmed.

[Inn-Spanish] Absorption

Absorbed from the small intestine by an active transport process

[Inn-Spanish] side effects and Toxicity

Mild gastrointestinal side effects including diarrhea. LD50 (rat) > 5,000 mg/kg.

[Inn-Spanish] Patient Information

No information avaliable

[Inn-Spanish] Organisms Affected

Humans and other mammals